SecBot SecBot

ESPR drug pipeline

Esperion Therapeutics, Inc. · 3 rated drugs
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±11.2%
1-day, median of 2 events
IV rank
No data
No current options data
Rated drugs
3
3 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercialized (since February 2020)

NEXLIZET bempedoic acid and ezetimibe Updated Jul 13

What to watch

ESPR common stock has been acquired by ARCHIMED at $3.16/share with the deal closing July 13, 2026. Holders received one non-transferable Contingent Value Right (CVR) per share, entitling them to potential milestone payments tied to NEXLETOL/NEXLIZET U.S. net sales (starting 2027) and ENBUMYST (through 2030). There is no further tradeable equity vehicle, the stock will be delisted.

Bull case
  • NEXLIZET has strong clinical validation from the landmark CLEAR Outcomes trial (nearly 14,000 patients, published in NEJM), demonstrating cardiovascular event reduction in both primary and secondary prevention patients regardless of statin use.
  • The March 2024 FDA label expansion made NEXLIZET and NEXLETOL the first oral non-statins approved for CV risk reduction in both primary and secondary prevention, a major commercial expansion of the addressable patient population.
  • Bempedoic acid received multiple Class 1 recommendations in the 2026 ACC/AHA Dyslipidemia Guidelines, which should drive further adoption by clinicians.
Bear case
  • The acquisition by ARCHIMED closed on July 13, 2026, ESPR common stock is being delisted, eliminating any further trading opportunity in the equity; the CVR is non-transferable and cannot be traded.
  • CVR milestone payments are contingent on achieving U.S. net sales targets for NEXLIZET/NEXLETOL (2027) and ENBUMYST (up to 2030), creating binary risk that milestones may not be met, resulting in zero additional value beyond the $3.16/share.
  • NEXLIZET competes in a structurally price-sensitive market dominated by cheap generic statins and generic ezetimibe; branded pricing relies on payer formulary placement and prior-authorization hurdles.
Explore drug →
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially marketed since February 2020

NEXLETOL bempedoic acid Updated Jul 13

What to watch

NEXLETOL is already approved and generating ~$160M in annual U.S. net product sales. But ESPR stock is now primarily an M&A arbitrage play: the company agreed to a $3.16/share cash buyout by ARCHIMED (expected close Q3 2026). With the stock trading at ~$3.18, the near-term upside is capped at the deal price plus potential CVR payments; the risk is deal delay or collapse. The drug itself has no pending binary catalyst, the commercial story is about guideline adoption and formulary access, not a regulatory event.

Bull case
  • CLEAR Outcomes trial showed NEXLETOL reduced major adverse cardiovascular events (MACE-4) by 13% vs placebo in statin-intolerant patients, with stronger effects on heart attacks (-23%) and coronary revascularization (-19%), supporting a powerful value proposition.
  • Received multiple Class 1 recommendations (highest level) in the 2026 ACC/AHA Multisociety Guideline for dyslipidemia management, which should drive guideline-directed prescribing.
  • Patent settlements with Dr. Reddy's and other ANDA filers prevent generic competition until at least April 2040, providing long U.S. market exclusivity.
Bear case
  • Analyst consensus is heavily bearish: 0 Buy, 8 Hold, 1 Sell, 2 Strong Sell. Needham downgraded Buy→Hold and HC Wainwright downgraded Buy→Neutral in May 2026, signaling limited conviction in organic upside.
  • NEXLETOL's LDL-C reduction (~18% on top of statins) is modest compared to PCSK9 inhibitors like Repatha/Praluent (injectables, ~60% reduction) or Leqvio (twice-yearly injectable), limiting its niche.
  • The addressable market is largely confined to statin-intolerant patients, about 5-10% of the ~35M US statin users, which constrains peak sales potential vs blockbuster cardiovascular drugs.
Explore drug → Trials (1)
● neutral
Impact
PhaseApproved
Time to marketAlready FDA-approved and launched (FDA approval September 14, 2025)

ENBUMYST bumetanide Updated Jul 13

What to watch

ESPR has been delisted following ArchiMed's acquisition at $3.16/share. Former shareholders received one non-transferable CVR per share, tied to U.S. sales milestones for ENBUMYST and bempedoic acid products through 2030. There is no public equity vehicle to trade for exposure to this drug's commercial performance.

Bull case
  • ENBUMYST is the first FDA-approved intranasal loop diuretic, a novel delivery format for a well-established drug, with 33% faster absorption than oral bumetanide.
  • The addressable U.S. market for outpatient diuretic therapy in edema is estimated at a multi-billion-dollar opportunity, targeting ~6.7 million American adults with heart failure (sources: Corstasis BusinessWire press release, Intellectia.AI).
  • Patents extend to at least December 2040–May 2045, providing long exclusivity runway for the nasal spray formulation (source: Drugs.com, GreyB patent analysis).
Bear case
  • ESPR is delisted and taken private, there is no publicly traded stock to invest in for this drug. Former shareholders received $3.16/share cash plus non-transferable CVRs with uncertain payout.
  • Bumetanide itself is a generic drug first FDA-approved in 1983, the innovation is purely the delivery format, not a new molecular entity, which may limit pricing power and reimbursement. Oral and IV bumetanide generics are widely available.
  • The Corstasis acquisition cost $75M upfront plus up to $180M in milestones and ongoing royalties, a meaningful cash outlay for a product entering a competitive diuretic market with established cheap alternatives (source: Fierce Pharma / Investing.com).
Explore drug →

Past FDA events & how the stock moved

2 events
DateDrugEvent1 day5 days
Feb 26, 2020NEXLIZETApproval−12.7%−12.9%
Feb 21, 2020NEXLETOLApproval−9.6%−16.5%

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
NEXLETOLA Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)Phase 2Completed · results31Jun 4, 2025